Automate Your Wheel Strategy on SNWV
With Tiblio's Option Bot, you can configure your own wheel strategy including SNWV - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SNWV
- Rev/Share 4.2339
- Book/Share -2.023
- PB -12.9683
- Debt/Equity -0.048
- CurrentRatio 0.3984
- ROIC -0.4618
- MktCap 224456691.0
- FreeCF/Share -0.0819
- PFCF -320.6524
- PE -6.8957
- Debt/Assets 0.0269
- DivYield 0
- ROE 1.0016
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Sanuwave Health Appoints Industry Veteran Dustin Libby as Executive Vice President of Commercial Operations
SNWV
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
Published: June 03, 2025 by: GlobeNewsWire
Sentiment: Neutral
EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ:SNWV), a leading provider of next-generation FDA-approved wound care products, is pleased to announce the hiring of Dustin Libby as its EVP of commercial operations.
Read More
About SANUWAVE Health, Inc. (SNWV)
- IPO Date 2009-09-30
- Website https://www.sanuwave.com
- Industry Medical - Devices
- CEO Mr. Morgan C. Frank
- Employees 46
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.